These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Use of hybridization kinetics for differentiating specific from non-specific binding to oligonucleotide microarrays. Dai H; Meyer M; Stepaniants S; Ziman M; Stoughton R Nucleic Acids Res; 2002 Aug; 30(16):e86. PubMed ID: 12177314 [TBL] [Abstract][Full Text] [Related]
8. Liver as a target for oligonucleotide therapeutics. Sehgal A; Vaishnaw A; Fitzgerald K J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039 [TBL] [Abstract][Full Text] [Related]
9. Polyamine-oligonucleotide conjugates: a promising direction for nucleic acid tools and therapeutics. Menzi M; Lightfoot HL; Hall J Future Med Chem; 2015; 7(13):1733-49. PubMed ID: 26424049 [TBL] [Abstract][Full Text] [Related]
10. Insights from crystallographic studies into the structural and pairing properties of nucleic acid analogs and chemically modified DNA and RNA oligonucleotides. Egli M; Pallan PS Annu Rev Biophys Biomol Struct; 2007; 36():281-305. PubMed ID: 17288535 [TBL] [Abstract][Full Text] [Related]
11. Dual ligation hybridization assay for the specific determination of oligonucleotide therapeutics. Tremblay G; Khalafaghian G; Legault J; Nielsen P; Bartlett A Bioanalysis; 2011 Mar; 3(5):499-508. PubMed ID: 21388263 [TBL] [Abstract][Full Text] [Related]
12. Targeted random mutagenesis: the use of ambiguously synthesized oligonucleotides to mutagenize sequences immediately 5' of an ATG initiation codon. Matteucci MD; Heyneker HL Nucleic Acids Res; 1983 May; 11(10):3113-21. PubMed ID: 6304623 [TBL] [Abstract][Full Text] [Related]
13. Cytokines and therapeutic oligonucleotides. Hartmann G; Bidlingmaier M; Eigler A; Hacker U; Endres S Cytokines Cell Mol Ther; 1997 Dec; 3(4):247-56. PubMed ID: 9740353 [TBL] [Abstract][Full Text] [Related]
14. Oligonucleotide therapeutics: chemistry, delivery and clinical progress. Sharma VK; Watts JK Future Med Chem; 2015; 7(16):2221-42. PubMed ID: 26510815 [TBL] [Abstract][Full Text] [Related]
15. Locked nucleic acids: a promising molecular family for gene-function analysis and antisense drug development. Orum H; Wengel J Curr Opin Mol Ther; 2001 Jun; 3(3):239-43. PubMed ID: 11497347 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic Oligonucleotides: An Outlook on Chemical Strategies to Improve Endosomal Trafficking. Mangla P; Vicentini Q; Biscans A Cells; 2023 Sep; 12(18):. PubMed ID: 37759475 [TBL] [Abstract][Full Text] [Related]
17. Control of complexity constraints on combinatorial screening for preferred oligonucleotide hybridization sites on structured RNA. Bruice TW; Lima WF Biochemistry; 1997 Apr; 36(16):5004-19. PubMed ID: 9125523 [TBL] [Abstract][Full Text] [Related]
18. Treating Disease at the RNA Level with Oligonucleotides. Levin AA N Engl J Med; 2019 Jan; 380(1):57-70. PubMed ID: 30601736 [No Abstract] [Full Text] [Related]
19. Binding of short oligonucleotides to RNA: studies of the binding of common RNA structural motifs to isoenergetic microarrays. Kierzek E Biochemistry; 2009 Dec; 48(48):11344-56. PubMed ID: 19835418 [TBL] [Abstract][Full Text] [Related]